The FDA reviews drug approval decisions that are expected in March 2025. The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback